SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) February 20, 2006
| | Progenics Pharmaceuticals, Inc. | |
| | | |
| | (Exact name of registrant as specified in its charter) | |
Delaware | | 000-23143 | | 13-3379479 | |
| | | | | | |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) | |
| | 777 Old Saw Mill River Road, Tarrytown, New York | 10591 |
| | | |
| | (Address of principal executive offices) | (Zip Code) |
Registrant's telephone number, including area code (914) 789-2800
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 1 - Registrant’s Business and Operations
Item 1.01 Entry into a Material Definitive Agreement.
At its meeting on February 20, 2006, the Compensation Committee of the Board of Directors of Progenics Pharmaceuticals, Inc. approved the following salary increases for 2006 and made the following cash bonus awards for 2005 to the specified named executive officers (as defined in Regulation S-K Item 402(a)(3)) of the Company:
Name | | | Title | | | 2005 Salary | | | 2006 Salary | | | Cash Bonus | |
| Mark R. Baker | | | Senior Vice President and General Counsel | | $ | 280,000 | | $ | 300,000 | | $ | 200,000 | |
| Robert J. Israel, M.D. | | | Senior Vice President, Medical Affairs | | | 312,000 | | | 325,000 | | | 125,000 | |
| Alton B. Kremer, M.D. | | | Vice President, Clinical Research | | | 320,000 | | | 340,000 | | | 125,000 | |
| Robert A. McKinney | | | Senior Vice President, Finance and Operations Chief Financial Officer | | | 230,000 | | | 250,000 | | | 150,000 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
PROGENICS PHARMACEUTICALS, INC.
By: /s/ Robert A. McKinney
Robert A. McKinney
Senior Vice President, Finance and Operations
Chief Financial Officer
Date: February 22, 2006
